ERBB2 and non-small cell lung carcinoma: Although a recent study indicated that EGFR-TKI treatment was associated with a significant increase in PD-L1 expression in EGFR-mutant NSCLC, the impact of cytotoxic chemotherapy is not excluded and specific to acquired HER2 amplification remains underdetermined (33).